Summit Trail Advisors LLC purchased a new position in iCAD, Inc. (NASDAQ:ICAD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 117,000 shares of the technology company's stock, valued at approximately $214,000. Summit Trail Advisors LLC owned 0.44% of iCAD at the end of the most recent reporting period.
Separately, waypoint wealth counsel boosted its position in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after acquiring an additional 4,400 shares during the last quarter. Institutional investors own 24.61% of the company's stock.
Shares of ICAD stock opened at $3.53 on Thursday. The stock has a market capitalization of $93.69 million, a price-to-earnings ratio of -27.15 and a beta of 1.47. iCAD, Inc. has a 12-month low of $1.18 and a 12-month high of $3.78. The stock's 50-day moving average price is $2.27 and its 200-day moving average price is $1.85.
Separately, StockNews.com downgraded shares of iCAD from a "hold" rating to a "sell" rating in a report on Wednesday.
View Our Latest Analysis on ICAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.